Massimo Serra

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5613776/publications.pdf

Version: 2024-02-01

133 papers	6,943 citations	46984 47 h-index	66879 78 g-index
133 all docs	133 docs citations	133 times ranked	8756 citing authors

#	Article	IF	Citations
1	Expression of P-Glycoprotein in High-Grade Osteosarcomas in Relation to Clinical Outcome. New England Journal of Medicine, 1995, 333, 1380-1385.	13.9	372
2	Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents. Clinical Cancer Research, 2011, 17, 2110-2119.	3.2	365
3	Antitumor Activity of the Insulin-Like Growth Factor-I Receptor Kinase Inhibitor NVP-AEW541 in Musculoskeletal Tumors. Cancer Research, 2005, 65, 3868-3876.	0.4	272
4	Modulation of the Osteosarcoma Expression Phenotype by MicroRNAs. PLoS ONE, 2012, 7, e48086.	1.1	253
5	An update on chemotherapy for osteosarcoma. Expert Opinion on Pharmacotherapy, 2015, 16, 2727-2736.	0.9	187
6	Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nature Genetics, 2013, 45, 799-803.	9.4	181
7	Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Laboratory Investigation, 2011, 91, 1195-1205.	1.7	155
8	Molecular characterization of commonly used cell lines for bone tumor research: A transâ€European EuroBoNet effort. Genes Chromosomes and Cancer, 2010, 49, 40-51.	1.5	141
9	miRâ€34a predicts survival of Ewing's sarcoma patients and directly influences cell chemoâ€sensitivity and malignancy. Journal of Pathology, 2012, 226, 796-805.	2.1	128
10	Local recurrence and local control of non-metastatic osteosarcoma of the extremities: A 27-year experience in a single institution. Journal of Surgical Oncology, 2007, 96, 118-123.	0.8	126
11	Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewingâ€™s sarcoma. European Journal of Cancer, 2005, 41, 1349-1361.	1.3	123
12	Overcoming Resistance to Conventional Drugs in Ewing Sarcoma and Identification of Molecular Predictors of Outcome. Journal of Clinical Oncology, 2009, 27, 2209-2216.	0.8	121
13	Overcoming Glutathione S-Transferase P1â€“Related Cisplatin Resistance in Osteosarcoma. Cancer Research, 2008, 68, 6661-6668.	0.4	113
14	Gene amplifications in osteosarcoma-CGH microarray analysis. Genes Chromosomes and Cancer, 2005, 42, 158-163.	1.5	108
15	Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Therapy, 2002, 9, 296-307.	2.2	101
16	Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma. Clinical Cancer Research, 2012, 18, 432-441.	3.2	97
17	Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. International Journal of Cancer, 2002, 101, 11-16.	2.3	96
18	Value of P-Glycoprotein and Clinicopathologic Factors as the Basis for New Treatment Strategies in High-Grade Osteosarcoma of the Extremities. Journal of Clinical Oncology, 2003, 21, 536-542.	0.8	95

#	Article	IF	Citations
19	Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor. Human Pathology, 1996, 27, 408-416.	1.1	94
20	Emerging drugs for high-grade osteosarcoma. Expert Opinion on Emerging Drugs, 2010, 15, 615-634.	1.0	92
21	Clinical relevance of Ki-67 expression in bone tumors. Cancer, 1995, 75, 806-814.	2.0	90
22	In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene, 2005, 24, 4349-4361.	2.6	90
23	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	1.4	90
24	A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma. Cancer Discovery, 2015, 5, 920-931.	7.7	88
25	Integrative Analysis Reveals Relationships of Genetic and Epigenetic Alterations in Osteosarcoma. PLoS ONE, 2012, 7, e48262.	1.1	87
26	LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization. Genes Chromosomes and Cancer, 2009, 48, 679-693.	1.5	84
27	Advances in emerging drugs for osteosarcoma. Expert Opinion on Emerging Drugs, 2015, 20, 495-514.	1.0	82
28	Integrins in glioblastoma: Still an attractive target?. Pharmacological Research, 2016, 113, 55-61.	3.1	82
29	Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma. Molecular Cancer Therapeutics, 2016, 15, 2640-2652.	1.9	82
30	Caveolin-1 Reduces Osteosarcoma Metastases by Inhibiting c-Src Activity and Met Signaling. Cancer Research, 2007, 67, 7675-7685.	0.4	81
31	Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunology, Immunotherapy, 2011, 60, 575-586.	2.0	76
32	Frequency and Implications of Chromosome 8 and 12 Gains in Ewing Sarcoma. Cancer Genetics and Cytogenetics, 1998, 100, 106-110.	1.0	75
33	IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. BMC Cancer, 2013, 13, 245.	1.1	73
34	c-kit Receptor Expression in Ewingâ€™s Sarcoma: Lack of Prognostic Value but Therapeutic Targeting Opportunities in Appropriate Conditions. Journal of Clinical Oncology, 2003, 21, 1952-1960.	0.8	71
35	Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines. Molecular BioSystems, 2012, 8, 994-1006.	2.9	69
36	Different simian virus 40 genomic regions and sequences homologous with SV40 large T antigen in DNA of human brain and bone tumors and of leukocytes from blood donors. Cancer, 2002, 94, 1037-1048.	2.0	65

#	Article	IF	Citations
37	A small-molecule RGD-integrin antagonist inhibits cell adhesion, cell migration and induces anoikis in glioblastoma cells. International Journal of Oncology, 2013, 42, 83-92.	1.4	63
38	Effect of TP53 Arg72Pro and MDM2 SNP309 Polymorphisms on the Risk of High-Grade Osteosarcoma Development and Survival. Clinical Cancer Research, 2009, 15, 3550-3556.	3.2	62
39	Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: Therapeutic prospects. International Journal of Cancer, 2004, 108, 358-366.	2.3	61
40	Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. Cancer Genetics and Cytogenetics, 2000, 123, 128-132.	1.0	60
41	CD99 Acts as an Oncosuppressor in Osteosarcoma. Molecular Biology of the Cell, 2006, 17, 1910-1921.	0.9	60
42	Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy. BMC Medical Genomics, 2014, 7, 4.	0.7	59
43	Prognostic Value of CCN3 in Osteosarcoma. Clinical Cancer Research, 2008, 14, 701-709.	3.2	58
44	Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer, 2009, 9, 17.	1.1	57
45	Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies. Cancers, 2021, 13, 2878.	1.7	56
46	Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21. Oncogene, 2002, 21, 2261-2269.	2.6	52
47	Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's Sarcoma Family of Tumors. International Journal of Cancer, 2011, 128, 1139-1150.	2.3	51
48	Small Molecule Integrin Antagonists in Cancer Therapy. Mini-Reviews in Medicinal Chemistry, 2009, 9, 1439-1446.	1.1	50
49	Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma. Cellular and Molecular Life Sciences, 2019, 76, 609-625.	2.4	50
50	Expression of insulin-like growth factor system components in Ewingâ€™s sarcoma and their association with survival. European Journal of Cancer, 2011, 47, 1258-1266.	1.3	49
51	Molecular profiling of chordoma. International Journal of Oncology, 2014, 44, 1041-1055.	1.4	49
52	Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma. Annals of Oncology, 2008, 19, 1500-1508.	0.6	48
53	Mechanisms of gene amplification and evidence of coamplification in drugâ€resistant human osteosarcoma cell lines. Genes Chromosomes and Cancer, 2009, 48, 289-309.	1.5	46
54	Identification of a potent and selective Ïƒ1 receptor agonist potentiating NGF-induced neurite outgrowth in PC12 cells. Bioorganic and Medicinal Chemistry, 2011, 19, 6210-6224.	1.4	45

#	Article	IF	Citations
55	Î³-Irradiation of PEGd,lPLA and PEG-PLGA Multiblock Copolymers: I. Effect of Irradiation Doses. AAPS PharmSciTech, 2008, 9, 718-25.	1.5	43
56	H₂S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance. Journal of Medicinal Chemistry, 2016, 59, 4881-4889.	2.9	43
57	Malignant fibrous histiocytoma of bone: Analysis of genomic imbalances by comparative genomic hybridisation and C-MYC expression by immunohistochemistry. European Journal of Cancer, 2006, 42, 1172-1180.	1.3	42
58	New model for bone resorption study in vitro: Human osteoclast-like cells from giant cell tumors of bone. Journal of Bone and Mineral Research, 1994, 9, 1013-1020.	3.1	42
59	Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma. Oncotarget, 2016, 7, 61970-61987.	0.8	41
60	Identification of RC-33 as a potent and selective Ïƒ1 receptor agonist potentiating NGF-induced neurite outgrowth in PC12 cells. Part 2: g-Scale synthesis, physicochemical characterization and in vitro metabolic stability. Bioorganic and Medicinal Chemistry, 2013, 21, 2577-2586.	1.4	37
61	Evaluation of osteonectin as a diagnostic marker of osteogenic bone tumors. Human Pathology, 1992, 23, 1326-1331.	1.1	36
62	Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques. European Journal of Cell Biology, 2003, 82, 483-493.	1.6	36
63	The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Oncogene, 1999, 18, 739-746.	2.6	35
64	Functionalized Keratin as Nanotechnology-Based Drug Delivery System for the Pharmacological Treatment of Osteosarcoma. International Journal of Molecular Sciences, 2018, 19, 3670.	1.8	34
65	Biological indicators of prognosis in Ewing's sarcoma: An emerging role for lectin galactosideâ€binding soluble 3 binding protein (LGALS3BP). International Journal of Cancer, 2010, 126, 41-52.	2.3	31
66	Genomeâ€wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients. International Journal of Cancer, 2018, 142, 1594-1601.	2.3	31
67	Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells. PLoS ONE, 2016, 11, e0166233.	1.1	31
68	Polyomavirus Latency and Human Tumors. Journal of Infectious Diseases, 1994, 169, 1175-1176.	1.9	30
69	Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41â€“60 years. Monthly Notices of the Royal Astronomical Society: Letters, 2007, 78, 377-384.	1.2	30
70	mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts. BMC Medical Genomics, 2011, 4, 66.	0.7	30
71	ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma. Cells, 2020, 9, 647.	1.8	30
72	Synthesis and chromatographic evaluation of molecularly imprinted polymers prepared by the substructure approach for the class-selective recognition of glucuronides. Journal of Chromatography A, 2011, 1218, 6961-6969.	1.8	29

#	Article	IF	Citations
73	Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance. Investigational New Drugs, 2014, 32, 1167-1180.	1.2	28
74	A Potent Integrin Antagonist from a Small Library of Cyclic RGD Pentapeptide Mimics Including Benzylâ€Substituted Azabicycloalkane Amino Acids. ChemMedChem, 2008, 3, 1589-1603.	1.6	27
75	Design, synthesis and SAR analysis of novel selective Ïƒ1 ligands (Part 2). Bioorganic and Medicinal Chemistry, 2010, 18, 1204-1212.	1.4	27
76	Stem-like Cancer Cells in a Dynamic 3D Culture System: A Model to Study Metastatic Cell Adhesion and Anti-cancer Drugs. Cells, 2019, 8, 1434.	1.8	27
77	New fast and practical method for the enantioselective synthesis of Î±-vinyl, Î±-alkyl quaternary Î±-amino acids. Tetrahedron: Asymmetry, 2008, 19, 247-257.	1.8	26
78	Inâ€Solution Structural Considerations by ¹H NMR and Solidâ€State Thermal Properties of Inulinâ€<scp>d</scp>â€Î±â€Tocopherol Succinate (INVITE) Micelles as Drug Delivery Systems for Hydrophobic Drugs. Macromolecular Chemistry and Physics, 2014, 215, 2084-2096.	1.1	26
79	Establishment and characterization of a primitive neuroectodermal tumor of bone continuous cell line (LAPâ€35). International Journal of Cell Cloning, 1990, 8, 409-424.	1.6	25
80	Excision repair crossâ€complementation group 1 protein expression predicts survival in patients with highâ€grade, nonâ€metastatic osteosarcoma treated with neoadjuvant chemotherapy. Histopathology, 2015, 67, 338-347.	1.6	24
81	Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients. Pharmacogenomics, 2016, 17, 2097-2114.	0.6	24
82	Doxorubicin-resistant osteosarcoma: novel therapeutic approaches in sight?. Future Oncology, 2017, 13, 673-677.	1.1	23
83	Murine model for skeletal metastases of Ewing's sarcoma. Journal of Orthopaedic Research, 2000, 18, 959-966.	1.2	22
84	Genetic analysis of fibrosarcoma of bone, a rare tumour entity closely related to osteosarcoma and malignant fibrous histiocytoma of bone. European Journal of Cell Biology, 2004, 83, 483-491.	1.6	22
85	Array comparative genomic hybridization reveals frequent alterations of G1/S checkpoint genes in undifferentiated pleomorphic sarcoma of bone. Genes Chromosomes and Cancer, 2011, 50, 291-306.	1.5	22
86	Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1449-1463.	1.5	22
87	Prenylated Curcumin Analogues as Multipotent Tools To Tackle Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2019, 10, 1420-1433.	1.7	21
88	Agave negatively regulates YAP and TAZ transcriptionally and post-translationally in osteosarcoma cell lines. Cancer Letters, 2018, 433, 18-32.	3.2	20
89	Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors. Cells, 2020, 9, 968.	1.8	19
90	Screening of fibrillogenesis inhibitors of Î²2-microglobulin: Integrated strategies by mass spectrometry capillary electrophoresis and in silico simulations. Analytica Chimica Acta, 2011, 685, 153-161.	2.6	17

#	Article	IF	Citations
91	Silk Fibroin Nanoparticle Functionalization with Arg-Gly-Asp Cyclopentapeptide Promotes Active Targeting for Tumor Site-Specific Delivery. Cancers, 2021, 13, 1185.	1.7	17
92	Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy. Analytical Cellular Pathology, 2011, 34, 131-45.	0.7	17
93	Frequent deletion of CDKN2A and recurrent coamplification of KIT, PDGFRA, and KDR in fibrosarcoma of boneâ€"An array comparative genomic hybridization study. Genes Chromosomes and Cancer, 2010, 49, 132-143.	1.5	16
94	Stereoselective Pd-Catalyzed Synthesis of Quaternary Î±-<scp>d</scp>-C-Mannosyl-(S)-amino Acids. Journal of Organic Chemistry, 2011, 76, 5247-5257.	1.7	16
95	Pre-Treatment of human osteosarcoma cells with N-methylformamide enhances P-glycoprotein expression and resistance to doxorubicin. International Journal of Cancer, 1994, 58, 95-101.	2.3	15
96	An RGD small-molecule integrin antagonist induces detachment-mediated anoikis in glioma cancer stem cells. International Journal of Oncology, 2018, 53, 2683-2694.	1.4	15
97	Palladiumâ€Catalyzed Asymmetric Decarboxylative Allylation of Azlactone Enol Carbonates: Fast Access to Enantioenriched Î±â€Allyl Quaternary Amino Acids. European Journal of Organic Chemistry, 2019, 2019, 732-741.	1.2	15
98	No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma. Anti-Cancer Drugs, 2006, 17, 411-415.	0.7	14
99	Prognostic Value of P-Glycoprotein in High-Grade Osteosarcoma. Journal of Clinical Oncology, 2007, 25, 4858-4860.	0.8	14
100	Copy number alterations and neoplasiaâ€specific mutations in MELK, PDCD1LG2, TLN1, and PAX5 at 9p in different neoplasias. Genes Chromosomes and Cancer, 2014, 53, 579-588.	1.5	14
101	Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 245-257.	1.5	14
102	Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma. International Journal of Molecular Sciences, 2020, 21, 4500.	1.8	14
103	Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma. Journal of Cancer Research and Clinical Oncology, 1992, 119, 121-126.	1.2	13
104	An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. BMC Cancer, 2014, 14, 137.	1.1	13
105	Synthesis of Easyâ€toâ€Functionalize AzaÂbicycloalkane Scaffolds as Dipeptide Turn Mimics en Route to cRGDâ€Based Bioconjugates. European Journal of Organic Chemistry, 2015, 2015, 7557-7570.	1.2	12
106	Establishment and characterization of in vivo orthotopic bioluminescent xenograft models from human osteosarcoma cell lines in Swiss nude and <scp>NSG</scp> mice. Cancer Medicine, 2018, 7, 665-676.	1.3	12
107	Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?. Expert Review of Molecular Diagnostics, 2018, 18, 947-961.	1.5	12
108	Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact. International Journal of Molecular Sciences, 2020, 21, 4659.	1.8	12

#	Article	IF	Citations
109	Synthesis of Variously Functionalized Azabicycloalkane Scaffolds by Domino Metathesis Reactions. Journal of Organic Chemistry, 2017, 82, 11091-11101.	1.7	11
110	A Combined Highâ€Resolution Mass Spectrometric and inâ€...silico Approach for the Characterisation of Small Ligands of Î²₂â€Microglobulin. ChemMedChem, 2010, 5, 1015-1025.	1.6	10
111	An Efficient Procedure Based on a MW-Assisted Hornerâ€“Wadsworth-Emmons Reaction for the Synthesis of (Z)-3,3-Trisubstituted-a,b-unsaturated Esters. Molecules, 2010, 15, 5928-5942.	1.7	10
112	Experimental design applied to the optimization of microwave-assisted DNA hydrolysis. Journal of Chromatography A, 2012, 1249, 8-16.	1.8	10
113	Allanblackia floribunda Oliv.: An aphrodisiac plant with vasorelaxant properties. Journal of Ethnopharmacology, 2016, 192, 480-485.	2.0	10
114	4-Demethoxy-3â€²-deamino-3â€²-aziridinyl-4â€²-methylsulphonyl-daunorubicin (PNU-159548): A promising new candidate for chemotherapeutic treatment of osteosarcoma patients. European Journal of Cancer, 2005, 41, 2184-2195.	1.3	9
115	Recent Advances in One-Pot Enyne Metathesis Processes for the Preparation of Biologically and Medicinally Relevant Compounds. Synthesis, 2021, 53, 785-804.	1.2	9
116	Impact of ABC Transporters in Osteosarcoma and Ewingâ€™s Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?. Cells, 2021, 10, 2461.	1.8	9
117	Polymer-Assisted Solution-Phase Synthesis Under Combined Ultrasound and Microwave Irradiation: Preparation of Î±,Î²-Unsaturated Esters and Carboxylic Acids, Key Intermediates of Novel Sigma Ligands. Synthetic Communications, 2009, 39, 3254-3262.	1.1	8
118	P53 oncosuppressor influences selection of genomic imbalances in response to ionizing radiations in human osteosarcoma cell line SAOS-2. International Journal of Radiation Biology, 2008, 84, 591-601.	1.0	7
119	Caveolins in the development and diseases of musculoskeletal system. Cancer Letters, 2009, 284, 113-121.	3.2	7
120	Oneâ€Pot Vinylation of Azlactones: Fast Access to Enantioenriched Î±â€Vinyl Quaternary Amino Acids. European Journal of Organic Chemistry, 2017, 2017, 2964-2970.	1.2	7
121	Visibleâ€Lightâ€Driven Competitive Stereoâ€•and Regioisomerization of (E)â€Î²â€Nitroenones. ChemPhotoChem, 2021, 5, 871-875.	1.5	7
122	Modulation of Amyloid Î²-Induced Microglia Activation and Neuronal Cell Death by Curcumin and Analogues. International Journal of Molecular Sciences, 2022, 23, 4381.	1.8	7
123	Beyond the affinity for protein kinase C: exploring 2-phenyl-3-hydroxypropyl pivalate analogues as C1 domain-targeting ligands. MedChemComm, 2015, 6, 547-554.	3.5	6
124	P-glycoprotein subcellular localization and cell morphotype in MDR1 gene-transfected human osteosarcoma cells. Biology of the Cell, 1999, 91, 17-28.	0.7	6
125	Synthesis of Functionalized 6,5- and 7,5-Azabicycloalkane Amino Acids by Metathesis Reactions. Journal of Organic Chemistry, 2019, 84, 15726-15734.	1.7	5
126	Controlled Decoration of [60]Fullerene with Polymannan Analogues and Amino Acid Derivatives through Malondiamide-Based Linkers. Molecules, 2022, 27, 2776.	1.7	4

#	Article	IF	Citations
127	Novel stereoselective syntheses of (2E,4E)-4-(4,4-dimethylpent-2-ynylidene)-N1,N5-dimethyl-N1,N5-bis(naphthalen-1-ylmethyl)pent-2-ene-1,5-diamine. Tetrahedron, 2009, 65, 5838-5843.	1.0	3
128	Polymorphisms of genes related to metotrexate response and toxicity in high-grade osteosarcoma. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 123-123.	1.5	3
129	Bioassay-Guided Isolation of Nigracin, Responsible for the Tissue Repair Properties of Drypetes Klainei Stem Bark. Frontiers in Pharmacology, 2019, 10, 1541.	1.6	2
130	Cytoplasmic and nuclear localization sites of phosphatidylinositol 3-kinase in human osteosarcoma sensitive and multidrug-resistant Saos-2 cells. Histochemistry and Cell Biology, 1996, 106, 457-464.	0.8	2
131	Oneâ€Pot Preparation of Functionalized Azabicyclo[6.3.0]alkanone Amino Acids by Tandem Cross Enyne Metathesis/Ringâ€Closing Metathesis. European Journal of Organic Chemistry, 2020, 2020, 3568-3575.	1.2	1
132	Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. , 0, .		1
133	Prognostic Relevance of CCN3 in Bone Sarcomas. , 2010, , 223-243.		0